Relay Therapeutics
Relay Therapeutics, Inc. is a clinical-stage precision medicine company based in Cambridge, Massachusetts, focused on transforming the drug discovery process. The company employs a novel allosteric drug-discovery platform, known as Dynamo, which integrates advanced computational techniques with experimental methods to study protein motion and interactions. This innovative approach enables the identification and development of therapies targeting complex diseases, particularly in oncology. Relay Therapeutics is advancing a pipeline of product candidates, including RLY-1971, a small molecule inhibitor targeting SHP2, RLY-4008, a selective inhibitor of FGFR2 for advanced solid tumors, and RLY-PI3K1047, aimed at mutant variants of phosphoinositide 3-kinase alpha. Founded in 2015, the company aims to deliver life-changing therapies to patients by addressing previously intractable targets in precision oncology and genetic diseases.
Top Stages
1 past transactions
ZebiAI
Acquisition in 2021
ZebiAI is a biotechnology company that specializes in utilizing machine learning to enhance small molecule drug discovery. By leveraging extensive experimental DNA-encoded library data sets and high-quality protein-small molecule interaction data, ZebiAI aims to accelerate the process of target validation and facilitate the development of new therapeutics for unmet medical needs. The company's innovative approach applies machine learning algorithms at various stages of drug discovery, streamlining research efforts and ultimately contributing to advancements in therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.